Lv2
130 积分 2023-05-18 加入
984P Patient-relevant outcomes (PROs) from SACHI: A phase 3 trial of savolitinib (Savo) plus osimertinib (Osi) versus chemotherapy (Chemo) in EGFR-mutant (EGFRm) and MET-amplified (METamp) advanced NSCLC after progression on EGFR-TKIs
1个月前
已关闭
982P Osimertinib (osi) + savolitinib (savo) in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) with MET overexpression and/or amplification (OverExp/Amp) following progressive disease (PD) on osi: SAVANNAH Asian subset
1个月前
已关闭
375P Surufatinib (S) in combination with camrelizumab (C), nab-paclitaxel and gemcitabine (AG) as the first-line treatment in metastatic pancreatic cancer: Results from phase II part of a randomized, open-label, active-controlled, phase II/III study
1个月前
已关闭
Abstract for 23rd International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Singapore, September 21–24, 2025
1个月前
已关闭
Surufatinib combined with sintilimab and IBI310 for the treatment of high‐grade advanced‐neuroendocrine neoplasms: A single arm, open‐label, single‐center, phase II study
3个月前
已完结
Successful full-dose rechallenge after fruquintinib-associated posterior reversible encephalopathy syndrome
7个月前
已完结
皖公网安备34019202002308
